Thank you for your participation in the Frankfurt Cancer Conference 2024 and for making it a science event to remember!
About the conference
The Frankfurt Cancer Conference is a three-day on-site meeting of internationally leading cancer researchers as well as junior scientists and clinical oncologists. The main theme of the conference in 2024 is “Targeting the tumor-host interface”.
The ongoing translational research activities of the University Cancer Center (UCT) Frankfurt, the German Cancer Consortium (DKTK) in Frankfurt/Mainz and the Frankfurt Cancer Institute (FCI) provide the framework for the conference. International, national and local research activities will be presented with focus on the following topics:
- Metabolism at the tumor-host interface
- Targeted cell therapy
- Molecular drug discovery
- Modulating immunotherapy response
- Post-transcriptional disease mechanisms
- Exploitation of the tumor microenvironment
Target audience
The conference targets basic and translational researchers as well as oncologists who are interested in cancer biology, novel cancer therapies and mechanism-based clinical trials. We want to encourage both early-career cancer researchers as well as clinical oncologists to participate and present their work to the international community. There will be plenty of opportunities to interact with experts in the field of cancer research and to establish or deepen collaborations in an inspiring atmosphere.
Scientific Organizing Committee
Prof. Dr. Hubert Serve
Chair of Scientific Organizing Committee
Department of Medicine 2, Hematology/Oncology
University Cancer Center (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK) and DKFZ
Prof. Dr. Thomas Oellerich
Co-Chair of Scientific Organizing Committee
Department of Medicine 2, Hematology/Oncology
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
University Cancer Center (UCT) Frankfurt
Prof. Dr. Melek Canan Arkan
Georg-Speyer-Haus
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Prof. Dr. Peter Bader
Department of Pediatrics
University Cancer Center (UCT) Frankfurt
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Prof. Dr. Halvard B. Bönig
Department for Cellular Therapeutics / Cell Processing (GMP)
German Red Cross Blood Service Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Prof. Dr. Christian Brandts
Department of Medicine 2, Hematology/Oncology
University Cancer Center (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Prof. Dr. Christian Buchholz
Paul-Ehrlich-Institut (PEI)
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
PD Dr. med. Gesine Bug
Department of Medicine 2, Hematology/Oncology
University Cancer Center (UCT) Frankfurt
Goethe University Frankfurt
Prof. Dr. Florian Büttner
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Dr. Anjali Cremer
Department of Medicine 2, Hematology/Oncology
University Cancer Center (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Dr. Anne Fassl
Department of Urology
University Cancer Center (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
Prof. Dr. Fabian Finkelmeier
Department of Medicine 1, Gastroenterology/Pneumology/Endocrinology
University Cancer Center (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
Dr. Nicola Gökbuget
Department of Medicine 2, Hematology/Oncology
University Cancer Center (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Prof. Dr. Florian Greten
Georg-Speyer-Haus
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Dr. Ann-Christin Hau
Institute for Neurology (Edinger Institute)
University Cancer Center (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
Prof. Dr. Katharina Imkeller
Institute for Neurology (Edinger Institute)
University Cancer Center (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Prof. Dr. Jan-Henning Klusmann
Department of Pediatrics
University Cancer Center (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Prof. Dr. Stefan Knapp
Institute for Pharmaceutical Chemistry
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Dr. Konstantinos Kokkaliaris
Dr. Senckenberg Institute of Pathology
University Cancer Center (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Dr. Susanne Müller-Knapp
Institute for Pharmaceutical Chemistry
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
Prof. Dr. Karlheinz Plate
Institute for Neurology (Edinger Institute)
University Cancer Center (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Dr. Yvonne Reiss
Institute for Neurology (Edinger Institute)
University Cancer Center (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
PD Dr. Eva Rettinger
Department of Pediatrics
University Cancer Center (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Prof. Dr. Michael Rieger
Department of Medicine 2, Hematology/Oncology
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK) and DKFZ
Prof. Dr. Claus Rödel
Department of Radiation Therapy and Oncology
University Cancer Center (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Prof. Dr. Joachim Steinbach
Dr. Senckenberg Institute of Neurooncology
University Cancer Cancer (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Dr. Hannah Uckelmann
Department of Pediatrics
University Cancer Center (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Prof. Dr. Evelyn Ullrich
Department of Pediatrics
University Cancer Cancer (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
German Cancer Consortium (DKTK)
Prof. Dr. Janne Vehreschild
Department of Medicine 2, Hematology/Oncology
Frankfurt Cancer Institute (FCI)
University Cancer Cancer (UCT) Frankfurt
Goethe University Frankfurt
German Cancer Consortium (DKTK)
PD Dr. Pia Zeiner
Dr. Senckenberg Institute of Neurooncology
University Cancer Cancer (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK)
Confirmed Speakers
Iannis Aifantis
Chair, Department of Pathology
NYU Grossman School of Medicine
New York, US
Scott Armstrong
Dana-Farber Cancer Institute,
Harvard Medical School,
Boston, US
Jay Bradner
Harvard Medical School
Boston, US
Luca Cifarelli
Institute for Experimental Pediatric Hematology and Oncology
Goethe University, Frankfurt,
Frankfurt, DE
Alessio Ciulli
Professor of Chemical and Structural Biology
University of Dundee
Dundee, Scotland, UK
Jiri Eitler
Experimental Transfusion Medicine,
Faculty of Medicine Carl Gustav Carus,
Dresden University of Technology
Institute for Transfusion Medicine
Dresden, DE
Eran Elinav
Department of Systems Immunology
Weizmann Institute of Science
Rehovot, IL
Sarah-Maria Fendt
VIB KU Leuven Center for Cancer Biology
Leuven, BE
Lydia Finley
Geoffrey Beene Junior Faculty Chair
Memorial Sloan Kettering Cancer Center
New York, US
Michaela Frye
German Cancer Research Center (DKFZ)
Heidelberg, DE
Stephen Gottschalk
Chair, Department of Bone Transplant and Cellular Therapy
St. Jude Children’s Research Hospital
Memphis, US
Florian Greten
Georg-Speyer-Haus Institute for Tumor Biology and Experimental Therapy
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
Frankfurt, DE
Michael Hallek
Department of Hematology/Oncology
University Hospital of Cologne
Cologne, DE
Daniel Hodson
Department of Haematology,
University of Cambridge,
Cambridge, UK
Lena Horvath
Department of Internal Medicine V, Hematology/Oncology
Medical University Innsbruck
Innsbruck, AT
Brian Huntly
Department of Hematology
University of Cambridge
Cambridge, UK
Katharina Imkeller
Institute for Neurology (Edinger Institute)
Goethe University Frankfurt
Frankfurt, DE
Pauline Jeannot
Department of Laboratory Medicine,
Division of Translational Cancer Research,
Lund University
Lund, SE
Michael Kharas
Memorial Sloan Kettering Cancer Center
New York, US
Rama Khokha
Department of Medical Biophysics
University of Toronto
Toronto, CA
Jan-Henning Klusmann
Department of Pediatrics,
Goethe University,
Frankfurt, DE
Stefan Knapp
Institute for Pharmaceutical Chemistry
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
Frankfurt, DE
Ravi Majeti
Director, Stanford Institute for Stem Cell Biology
and Regenerative Medicine
Stanford, US
Thomas Oellerich
Department of Medicine 2, Hematology/Oncology,
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
Frankfurt, DE
James Phelan
Lymphoid Malignancies Branch
National Cancer Institute (NIH)
Bethesda, US
Christian Reinhardt
Department of Hematology and Stem Cell Transplantation
University Hospital Essen
Essen, DE
Rizwan Romee
Principal Investigator
Dana-Farber Cancer Institute
Boston, US
Marco Ruella
Center for Cellular Immunotherapies
University of Pennsylvania
Philadelphia, US
Luisa Schäfer
Department of General and Visceral Surgery,
University of Freiburg
Freiburg, DE
Bastian Schilling
Department of Dermatology
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
Frankfurt, DE
Hubert Serve
Department of Medicine 2, Hematology/Oncology
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
Frankfurt, DE
Sapir Shcoory
Department of Immunology & Regenerative Biology,
Weizmann Institute of Science
Rehovot, IL
Zuzana Tatarova
Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy,
Frankfurt, DE
Mélanie Tichet
Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy,
Frankfurt, DE
Yuki Toda
Laboratory of Clinical and Translational Physiology,
Kyoto Pharmaceutical University
Kyoto, JP
Hannah Uckelmann
Department of Pediatrics
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
Frankfurt, DE
Evelyn Ullrich
Department of Pediatrics
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
Frankfurt, DE
Marcel R. M. van den Brink
City of Hope
Los Angeles, US
Georg E. Winter
Center for Molecular Medicine
Medical University Vienna
Vienna, AT
| TIME | CONFERENCE PROGRAM – Wednesday, 28 August 2024 | 12:00 - 19:15 CEST |
|---|---|
| 12:00-14:00 | Arrival and Registration |
| 14:00 | Welcome & Introduction Hubert Serve, Goethe University Frankfurt, DE |
| 14:10-15:45 | Opening Session Session Chairs: Thomas Oellerich & Evelyn Ullrich |
| 14:10-14:40 | Michael Hallek, University Hospital of Cologne, DE: Therapeutic concepts for chronic lymphocytic leukemia derived from insights on the molecular and cellular pathology |
| 14:40-15:10 | Marcel van den Brink, City of Hope, Los Angeles, US: The role of the intestinal microbiome in cancer immunotherapy |
| 15:10-15:35 | Hannah Uckelmann, Goethe University Frankfurt, DE: Targeting epigenetic mechanisms of leukemic transformation |
| 15:35-15:45 | Zuzana Tatarova, Georg-Speyer-Haus, Frankfurt, DE: Short talk: Finding the tumor microenvironmental role in therapy efficacy by MIMA |
| 15:45-16:35 | Coffee Break |
| 16:35-17:25 | Keynote Lecture Introduction: Stefan Knapp Jay Bradner, Harvard Medical School, Boston, US: Chemical biology and cancer therapeutics |
| 17:25-19:00 | Session 1 – Targeted Cell Therapy Session Chairs: Eva Rettinger & Torsten Tonn |
| 17:25-17:55 | Stephen Gottschalk, St. Jude Children’s Research Hospital, Memphis, US: Synthetic T-cell therapy for pediatric cancer |
| 17:55-18:25 | Rizwan Romee, Dana-Farber Cancer Institute, Boston, US: Novel approaches to tumor microenvironment modulation for enhanced cancer immunotherapy |
| 18:25-18:50 | Evelyn Ullrich, Goethe University Frankfurt, DE: Genetic engineering of NK cells for personalized immunotherapy |
| 18:50-19:00 | Jiri Eitler, Dresden University of Technology, Dresden, DE: Short talk: Dual targeting of PD-L1 and ErbB2 by CAR-NK cells enables specific elimination of solid tumor cells and overcomes immune escape via antigen loss |
| 19:00-19:15 | Closing Remarks |
| TIME | CONFERENCE PROGRAM – Thursday, 29 August 2024 | 08:30 - 19:30 CEST |
|---|---|
| 08:30-09:00 | Arrival and Registration |
| 09:00-09:05 | Welcome |
| 09:05-10:35 | Session 2 – Modulating Immunotherapy Response Session Chairs: Florian Greten & Darja Karpova |
| 09:05-09:35 | Eran Elinav, Weizmann Institute of Science, Rehovot, IL: Host-microbiome interaction in health and disease |
| 09:35-10:05 | Lena Horvath, Medical University Innsbruck, AT: Neutrophils in NSCLC |
| 10:05-10:35 | Marco Ruella, University of Pennsylvania, Philadelphia, US: Catch me if you can: resistance to CAR-T therapy |
| 10:35-11:20 | Coffee Break |
| 11:20-13:00 | Session 3 – Exploitation of Tumor-intrinsic Mechanisms Session Chairs: Jan-Henning Klusmann & Marit Vermunt |
| 11:20-11:50 | Ravi Majeti, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford, US: Stem cells and reprogramming in human AML |
| 11:50-12:20 | James Phelan, National Cancer Institute (NIH), Bethesda, US: Leveraging functional genomics for precision medicine |
| 12:20-12:30 | Luca Nunzio Cifarelli, Goethe University Frankfurt, DE: Short talk: The activation of TP53 pathway is a therapeutic vulnerability in NUP98::KDM5A+ Pediatric Non-Down Syndrome AMKL |
| 12:30-13:00 | Brian Huntly, University of Cambridge, UK: CREBBP-mutations rewire metabolism within lymphoid malignancies generating therapeutic vulnerabilities |
| 13:00-15:00 | Lunch Break and Poster Session I |
| 15:00-16:35 | Session 4 – Post-transcriptional Disease Mechanisms Session Chairs: Joachim Steinbach & Zuzana Tatarova |
| 15:00-15:30 | Michael Kharas, Memorial Sloan Kettering Cancer Center, New York, US: Regulators that orchestrate RNA and cellular fates |
| 15:30-16:00 | Michaela Frye, German Cancer Research Center (DKFZ), Heidelberg, DE: Targeting RNA modifications in cancer |
| 16:00-16:10 | Katharina Imkeller, Goethe University Frankfurt, DE: Short talk: Multi-omic characterization of B-cell infiltration and tertiary lymphoid structures in glial tumors |
| 16:10-16:35 | Thomas Oellerich, Goethe University Frankfurt, DE: Identification of high-risk lymphoma by proteogenomics |
| 16:35-17:10 | Coffee Break |
| 17:10-19:15 | Session 5 – Metabolism at the Tumor-Host Interface Session Chairs: Melek Canan Arkan & Michael Rieger |
| 17:10-17:40 | Iannis Aifantis, NYU Grossman School of Medicine, New York, US: Spatial mapping of the interaction between leukemia and its microenvironment |
| 17:40-18:05 | Hubert Serve, Goethe University Frankfurt, DE: Protein and amino acid metabolism in AML |
| 18:05-18:35 | Lydia Finley, Memorial Sloan Kettering Cancer Center, New York, US: Metabolic control of cancer cell identity |
| 18:35-18:45 | Luisa Schäfer, University of Freiburg, DE: Short talk: Single cell deconvolution of metastatic stage IV colorectal cancer |
| 18:45-19:15 | Sarah-Maria Fendt, VIB-KU Leuven Center for Cancer Biology, Leuven, BE: Metabolic rewiring driving metastasis formation |
| 19:15-19:30 | Closing Remarks |
| 19:30 | Conference Dinner |
| TIME | CONFERENCE PROGRAM – Friday, 30 August 2024 | 08:30 - 17:30 CEST |
|---|---|
| 08:30-09:00 | Arrival and Registration |
| 09:00-09:05 | Welcome |
| 09:05-10:50 | Session 6 – Innovative Therapeutics Session Chairs: Aimo Kannt & Susanne Müller-Knapp |
| 09:05-09:30 | Jan-Henning Klusmann, Goethe University Frankfurt, DE: Multiomics-based framework to categorize pediatric acute myeloid leukemia |
| 09:30-10:00 | Scott Armstrong, Dana-Farber Cancer Institute, Harvard Medical School, Boston, US: Innovative therapies for high-risk AML |
| 10:00-10:10 | Sapir Shcoory, Weizmann Institute of Science, Rehovot, IL: Short talk: Targeted TACE (ADAM17) inhibition of lung cancer fibrotic microenvironment by a bacteria-based delivery system |
| 10:10-10:40 | Daniel Hodson, University of Cambridge, UK: Deciphering the genomics of aggressive lymphomas |
| 10:40-10:50 | Pauline Jeannot, Lund University, Lund, SE: Short talk: Targeting of astrocyte reactivity in brain tumors to prevent radioresistance |
| 10:50-11:35 | Coffee Break |
| 11:35-13:00 | Session 7 – Molecular Drug Discovery Session Chairs: Christian Brandts & Anne Wilke |
| 11:35-12:05 | Alessio Ciulli, University of Dundee, Scotland, UK: How degraders work: molecular recognition and design principles |
| 12:05-12:30 | Stefan Knapp, Goethe University Frankfurt, DE: Selective protein degradation as a new pharmacological modality for cancer drug development |
| 12:30-13:00 | Georg Winter, Medical University Vienna, AT: Identification and characterization of molecular glue degraders |
| 13:00-15:00 | Lunch Break and Poster Session II |
| 15:00-17:05 | Session 8 – Exploitation of the Tumor Microenvironment Session Chairs: Anne Fassl & Claus Rödel |
| 15:00-15:30 | Rama Khokha, University of Toronto, CA: Breaking down the PDAC tumor microenvironment |
| 15:30-15:40 | Yuki Toda, Kyoto Pharmaceutical University, Kyoto, JP: Short talk: Dysregulated acidity of pre-metastatic niche targeted by pH Low Insertion Peptide |
| 15:40-16:10 | Christian Reinhardt, University Hospital Essen, DE: Functional synapses between small cell lung cancer cells and glutamatergic neurons |
| 16:10-16:35 | Florian Greten, Georg-Speyer-Haus, Frankfurt, DE: Targeting the stroma of colorectal cancer |
| 16:35-16:55 | Bastian Schilling, Goethe-University Frankfurt, DE: Leveraging mutated and cryptic neoantigens: new approaches in melanoma immunotherapy |
| 16:55-17:05 | Mélanie Tichet, Georg-Speyer-Haus, Frankfurt, DE: Short talk: Reprogramming immunosuppressive tumor-associated macrophages potentiates standard-of-care therapy in melanoma |
| 17:05-17:30 | Poster Prize Award Wrap-up End of Conference |
Registration
The participation fee for the Frankfurt Cancer Conference is 438 EUR. This fee includes:
- Access to all conference sessions
- All conference material (program & abstract book)
- Coffee breaks, lunches and finger food on August 28-30, 2024
- Conference dinner on August 29, 2024
- Free WLAN at conference venue
Please note that the conference fee is an all-inclusive package and not discountable.
Please contact us directly if you need
- on-site child care or
- any kind of assistance with accessibility matters.
Accommodation is not included in the registration fee.
Registration deadline
Extended registration deadline: July 14, 2024
Registration will be closed after the limit of 400 registered participants is reached.
Terms and Conditions
Registration and Payment
The participant's registration will only be accepted with payment of the registration fee of 438 EUR. Payment is made via Paypal whereby the terms of use of Paypal apply. A PayPal account is not absolutely necessary; the payment process via PayPal also allows credit card and direct debit as a payment method. The registration is processed using IDLoom whereby the terms and conditions of IDLoom apply.
Substitutions and Cancellation
Full refunds of the conference registration fee will only be offered for cancellations made in writing and only prior to the registration deadline (June 30, 2024). After this deadline, cancellation and refunds will only be made in exceptional circumstances at the discretion of the conference organizers. In case of cancellation, it is possible to nominate a substitute delegate from the same organization. Delegate changes are only accepted in writing. Any cancellation or substitution requests should be emailed to the Conference Manager at info-fcc@ukffm.de.
Please note that you are responsible for organizing your own arrival and departure and that the organizer accepts no liability for the cancellation of flight or train tickets or accommodation booked by you.
Cancellation of Frankfurt Cancer Conference
If the conference should be cancelled for any reason, we will credit 100% of paid registration fees.
Program Changes
No liability is accepted for changes to the program or postponements. The organizers reserve the right to postpone or to cancel individual lectures or other program elements should this become necessary. This does not give the participant the right to withdraw. Furthermore, the organizers are not liable for the presence of announced speakers. In the event of cancellation or postponement of individual lectures or other program elements, the participant shall not be entitled to compensation of any kind. The organizers will then endeavour to find adequate replacement.
Privacy Policy
By registering for the conference, the participant agrees to allow the use and storage of his/her personal data for the purpose of processing the registration and conference fees. Furthermore, the participant consents to receive information by email and telephone in connection with the participation in the conference. The data will not be used for purposes other than the participation in the Frankfurt Cancer Conference. After the conference has been completed, the personal data of the participants will be deleted. In exceptional cases, personal data may be stored after the end of the conference until it is no longer required for the processing of the work that has arisen (e.g. problems have arisen or participants still have questions and these still need to be resolved in contact with the participant).
The organizer and its registration processor idloom process your data in compliance with European GDPR. The information you have provided upon registration is necessary to organize the event you will be attending, to generate invoices, to confirm your registration by e-mail, to create your badge and to allow you to modify your registration. You are entitled to object to these processing operations.
idloom shall only process User’s personal data in the European Union, or in third countries after having secured appropriate guaranties with the subcontractor or recipient. They are transferred to the country of the organizer. The organizer will keep your data after the event until the expiry of the legal retention obligations, in particular fiscal and accounting and until the end of the responsibility.
You can obtain from the organizer (info-fcc@ukffm.de) the written communication of your data, as well as, where appropriate, portability of the data, rectification, restriction of processing, deletion of data which is inaccurate, incomplete or irrelevant. For further information or to lodge a complaint you may also contact our official data protection officer at the Goethe University Frankfurt am Main (dsb@uni-frankfurt.de) and the Hessian data protection officer (poststelle@datenschutz.hessen.de).
Creation, use, editing and publication of photographs and videos
Photos and videos will be taken during the event for public relations purposes. By selecting the checkbox upon registration, you agree that the photos and videos taken in connection with the event may be published, used, edited and reproduced by the organizer for representation purposes on the intranet, on the Internet (including social media platforms) and in print and presentation media without any claim to remuneration. This consent is voluntary and can be changed or completely revoked at any time in writing to the organizer with effect for the future. We would like to point out that participants who do not agree to this will be assigned a special seat during the conference.
Disclaimer
Please note that the organizers shall not be responsible for and shall be exempt from any and all liability in respect of any damage, injury or accident of any person on the way to or during the conference, or for loss or damage to his or her luggage or any other property. All insurance, including medical cover or expenses incurred in the event of the cancellation of the Frankfurt Cancer Conference are the responsibility of the participant himself. Participants are encouraged to choose a travel insurance policy that includes loss of fees/deposit through cancellation of your participation in Frankfurt Cancer Conference, or through the cancellation of the event itself, loss of airfares for any reason, medical expenses, loss or damage to personal property, additional expenses and repatriation should travel arrangements have to be altered. The Organizing Committee will take no responsibility for any participant failing to insure.
Abstract Submission
Abstract submission has been closed.
Selection of abstracts for poster presentations will be based on their scientific impact on the conference. After the assessment of the abstracts by the Scientific Organizing Committee, authors will receive an email notification and will be informed of acceptance and selection for poster presentation.
Posters
All accepted participants are invited to present a poster. Posters should be printed in DIN A0, which is 84.1 cm (width) x 118.9 cm (height). Poster stripes and pins for poster setup will be provided at the conference venue.
Conference venue
Goethe University Frankfurt
Westend Campus
Theodor-W.-Adorno-Platz 1
60323 Frankfurt am Main
Casino building
Festsaal I (Room 823)
accessible by foot via Nina-Rubinstein-Weg
Transport & Directions
The Campus Westend of the Goethe University Frankfurt is well-connected to the international airport of Frankfurt (FRA) and reachable by taxi (20 min) or public transport (35 min).
The Deutsche Bahn (www.bahn.de) offers railway services from German and European cities directly to the Frankfurt Main Station, which is connected to Campus Westend by a 10 min subway ride.
Detailed information on public transportation in Frankfurt: www.rmv.de
Travel by plane
Flight to Frankfurt International Airport (FRA)
Taxi ride to Campus Westend (20 min) or
Public transportation with S8 or S9 to “Hauptwache” and then U1/U2/U3/U8 to “Holzhausenstraße”, 0.5 km walk to Campus Westend
Travel by train
Train ride to Frankfurt Main Station (“Frankfurt Hauptbahnhof”)
Public transportation with S1-9 to “Hauptwache” and then U1/U2/U3/U8 to “Holzhausenstraße”, 0.5 km walk to Campus Westend
Travel by car
Address for navigation system: Theodor-W.-Adorno-Platz 1, 60323 Frankfurt am Main
Parking has to be organized individually by the participants.There are no reserved parking lots at the conference venue. Several car parks are in the immediate vicinity of the conference (<1 km):
- Parkhaus Palmengarten, Siesmayerstraße 61, 60323 Frankfurt am Main
- Parkhaus Grünhof APCOA, Eschersheimer Landstraße 223, 60320 Frankfurt am Main
- Parkhaus Turmcenter, Querstraße 7-9, 60547 Frankfurt am Main
Contact
Chairs of the Scientific Organizing Committee
Prof. Dr. Hubert Serve
Department of Medicine 2, Hematology/Oncology
University Cancer Center (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK) and DKFZ
Prof. Dr. Thomas Oellerich
Department of Medicine 2, Hematology/Oncology
University Cancer Center (UCT) Frankfurt
Frankfurt Cancer Institute (FCI)
Goethe University Frankfurt
German Cancer Consortium (DKTK) and DKFZ
Conference Managers
Dr. Angelika Oellerich
a.oellerich@med.uni-frankfurt.de
Tel: +49 (0)69 / 6301-5459
Birgit Rosiejak
rosiejak@em.uni-frankfurt.de
Tel: +49 (0)69 / 6301-5459
Press Relations
Felicitas Cremer
felicitas.cremer@med.uni-frankfurt.de
Tel: +49 (0)69 / 6301-87335
The Frankfurt Cancer Conference is an advertising-free event. There will be no exhibition spaces or other advertising opportunities for industry sponsors.
